We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01523873
First Posted: February 1, 2012
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Guerbet
  Purpose
The main purpose of this study is to prospectively assess the general safety profile of Dotarem

Condition
General Safety Profile of DOTAREM

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)

Further study details as provided by Guerbet:

Primary Outcome Measures:
  • Frequency of Adverse Events [ Time Frame: During the time of usual follow-up post Dotarem administration (from less than 30 min to 1 hour after magnetic resonance examination). ]
    Adverse Events were notified and described.


Secondary Outcome Measures:
  • Nephrogenic Systemic Fibrosis Incidence [ Time Frame: Follow-up of at least 3 months after magnetic resonance examination ]
    For any patient identified with moderate to severe impaired renal function at the time of inclusion, a specific safety follow-up was performed in order to detect any suspicion of Nephrogenic Systemic Fibrosis.

  • Image Quality [ Time Frame: Up to 1 hour (as the duration of usual follow-up post Dotarem administration was from less than 30 min to 1 hour) ]
    Image quality was assessed by the radiologist using a scale with five classes: very poor, poor, fair, good and very good.

  • Diagnostic Quality [ Time Frame: Up to 1 hour (as the duration of usual follow-up post Dotarem administration was from less than 30 min to 1 hour) ]
    Diagnostic quality was assessed by the radiologist by answering the question "could you come to a diagnostic ?" (answer : yes or no).


Enrollment: 35921
Study Start Date: November 2008
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
All consecutive patients scheduled for a Dotarem®-enhanced MRI over a one year period at each participating radiological site
Criteria

Inclusion Criteria:

  • patient scheduled for a Dotarem®-enhanced MRI

Exclusion Criteria:

  • patient with a contra-indication to MR examination
  • patient with a contra-indication to Dotarem® injection as per local SPC
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01523873


Locations
Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Austria
Diagnosticum Gersthof
Vienna, Austria
China
Shanghai Pulmonary Hospital
Shanghai, China
France
Hôpital Necker
Paris, France
Germany
Universitätskliniken
Cologne, Germany
India
Bombay Hospital Institute of Medical Sciences
Mumbai, India
Italy
Ospedale Policlinico Giambattista Rossi
Verona, Italy
Saudi Arabia
Tabouk Military Hospital
Tabouk, Saudi Arabia
Spain
Complexo Hospitalario Xeral-Calde
Lugo, Spain
United Kingdom
Hull Royal Infirmary
Hull, United Kingdom
Sponsors and Collaborators
Guerbet
  More Information

Responsible Party: Guerbet
ClinicalTrials.gov Identifier: NCT01523873     History of Changes
Other Study ID Numbers: DGD-55-001
First Submitted: January 26, 2012
First Posted: February 1, 2012
Results First Submitted: December 14, 2015
Results First Posted: January 22, 2016
Last Update Posted: February 24, 2017
Last Verified: January 2017


To Top